ABI-008 Trial in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 85
- Registration Number
- NCT00531271
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 133
- Registration Number
- NCT00528983
- Locations
- 🇺🇸
Institute for Translational Oncology Research IRB, Greenville, North Carolina, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Prevention of Restenosis Following Revascularization
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT00518284
- Locations
- 🇺🇸
Michigan Vascular Research Center, Flint, Michigan, United States
🇺🇸Lindner Clinical Trials Center, Cincinnati, Ohio, United States
🇺🇸UC Davis Medical Center, Ellison Ambulatory Care Center Cardiology Suite 3400, Sacramento, California, United States
AVIDA The Vidaza® (Azacitidine) Patient Registry
- Conditions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Celgene
- Target Recruit Count
- 479
- Registration Number
- NCT00481273
- Locations
- 🇺🇸
AVIDA Registry Help, Kansas City, Missouri, United States
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT00478777
- Locations
- 🇩🇪
Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪EPS - Early Phase Solutions GmbH, Jena, Germany
🇩🇪Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen, Essen, Germany
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT00477529
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT00474188
- Locations
- 🇺🇸
Washington County Hospital, The Center for Clinical Research, Hagerstown, Maryland, United States
🇺🇸Oncology & Hematology Specialists, PA, Denville, New Jersey, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 88
- Registration Number
- NCT00463385
- Locations
- 🇦🇹
Medical University of Vienna, Department of Internal Medicine, Hematology, Vienna, Austria
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸New York Presbyterian HospitalWeill Medical College of Cornell University, New York, New York, United States
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT00461045
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 34
- Registration Number
- NCT00458159
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States